These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 38857214

  • 1. Prescription patterns and effectiveness of medications for chronic obstructive pulmonary disease: A retrospective study of real-world settings.
    Park HJ, Lee JU, Jeon S, Lee HS, Kim BY, Chae YJ, Kim GO, Park JW, Lee JH.
    PLoS One; 2024; 19(6):e0304362. PubMed ID: 38857214
    [Abstract] [Full Text] [Related]

  • 2. Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.
    Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA.
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [Abstract] [Full Text] [Related]

  • 3. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids.
    Liao PA, Pan SW, Chen CY, Deng CY, Dong YH.
    Int J Chron Obstruct Pulmon Dis; 2023 Apr; 18():553-563. PubMed ID: 37069844
    [Abstract] [Full Text] [Related]

  • 4. Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease.
    Petite SE.
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [Abstract] [Full Text] [Related]

  • 5. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A, Montes de Oca M, Menezes AM, Wehrmeister FC, Lopez Varela MV, Mendoza L, Ramírez L, Miravitlles M.
    Int J Chron Obstruct Pulmon Dis; 2018 Aug; 13():1545-1556. PubMed ID: 29785104
    [Abstract] [Full Text] [Related]

  • 6. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
    Asche CV, Leader S, Plauschinat C, Raparla S, Yan M, Ye X, Young D.
    Int J Chron Obstruct Pulmon Dis; 2012 Aug; 7():201-9. PubMed ID: 22500120
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
    Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, Holmgren U, de Nigris E.
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [Abstract] [Full Text] [Related]

  • 8. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
    Suissa S, Dell'Aniello S, Ernst P.
    Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
    [Abstract] [Full Text] [Related]

  • 9. Overuse of long-acting β2-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns.
    Brunton SA, Hogarth DK.
    Postgrad Med; 2023 Nov; 135(8):784-802. PubMed ID: 38032494
    [Abstract] [Full Text] [Related]

  • 10. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid.
    Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA.
    Ann Pharmacother; 2017 Nov; 51(11):945-953. PubMed ID: 28677404
    [Abstract] [Full Text] [Related]

  • 11. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
    Suissa S, Dell'Aniello S, Ernst P.
    Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966
    [Abstract] [Full Text] [Related]

  • 12. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.
    Lane DC, Stemkowski S, Stanford RH, Tao Z.
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1165-1172. PubMed ID: 30362922
    [Abstract] [Full Text] [Related]

  • 13. Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice.
    Suissa S, Dell'Aniello S, Ernst P.
    Chest; 2019 Jun; 155(6):1158-1165. PubMed ID: 30922950
    [Abstract] [Full Text] [Related]

  • 14. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators.
    Skolnik NS, Nguyen TS, Shrestha A, Ray R, Corbridge TC, Brunton SA.
    Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
    [Abstract] [Full Text] [Related]

  • 15. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
    Bogart M, Stanford RH, Reinsch T, Hull M, Buikema A, Hulbert E.
    Respir Med; 2018 Sep; 142():73-80. PubMed ID: 30170806
    [Abstract] [Full Text] [Related]

  • 16. Chronic obstructive pulmonary disease hospital admissions and drugs--unexpected positive associations: a retrospective general practice cohort study.
    Harries TH, Seed PT, Jones S, Schofield P, White P.
    NPJ Prim Care Respir Med; 2014 May 20; 24():14006. PubMed ID: 24842126
    [Abstract] [Full Text] [Related]

  • 17. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
    van Geffen WH, Tan DJ, Walters JA, Walters EH.
    Cochrane Database Syst Rev; 2023 Dec 06; 12(12):CD011600. PubMed ID: 38054551
    [Abstract] [Full Text] [Related]

  • 18. Comparing Costs and Healthcare Resource Utilization (HCRU) Using LAMA versus LABA/ICS at Treatment Initiation for COPD: Findings from CITRUS (Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea) Study.
    Choi KY, Kim HI, Rhee CK, Yoo KH, Park YB, Kim Y, Lee SE, Kim JA, Hwang YI.
    Int J Chron Obstruct Pulmon Dis; 2024 Dec 06; 19():1661-1671. PubMed ID: 39050737
    [Abstract] [Full Text] [Related]

  • 19. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.
    Bloom CI, Elkin SL, Quint JK.
    Int J Chron Obstruct Pulmon Dis; 2019 Dec 06; 14():279-287. PubMed ID: 30774325
    [Abstract] [Full Text] [Related]

  • 20. Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.
    Feldman WB, Avorn J, Kesselheim AS, Gagne JJ.
    JAMA Intern Med; 2023 Jul 01; 183(7):685-695. PubMed ID: 37213116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.